Johnson & Johnson
JNJNYSEPharmaceutical PreparationsFiscal year ends January 3
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Oct 21, 2026Score 12/3042% above fair value
$270.56−2.64 (-0.97%)
Close on Nov 2, 2026Market cap $652.02BP/E 31.4Yield 1.90%
Johnson & Johnson CAPLYTA (lumateperone) — International sales by Year
CAPLYTA (lumateperone) — International sales ($M) ($M)
Johnson & Johnson CAPLYTA (lumateperone) — International sales: $0M in FY2025.
Latest, FY2025
0
Period ended Dec 28, 2025
Change on a year earlier
–
0 in FY2024
History
3 years
Since FY2023
Sources
1
Form 10-K (filed 2026-02-11)
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-11) ↗
Reported in Form 10-Q / 10-K Segment Note & Form 8-K EX-99.2 Segment Sales Schedule.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | CAPLYTA (lumateperone) — International sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 28, 2025 | 0 | – | Form 10-K (filed 2026-02-11) ↗ |
| FY2024 | Dec 29, 2024 | 0 | – | Form 10-K (filed 2026-02-11) ↗ |
| FY2023 | Dec 31, 2023 | 0 | – | Form 10-K (filed 2026-02-11) ↗ |
Cite this data
StockData. (2026). Johnson & Johnson CAPLYTA (lumateperone) — International sales ($M), annual FY2023–FY2025 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/drug-caplyta-intl
See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.